In order to focus on precise diagnosis and treatment of cardiovascular diseases, this medical company has signed a number of cooperation agreements in the near future

At present, cardiovascular disease has become a major “killer” that seriously threatens the health of Chinese residents.
Statistics from the National Cardiovascular Center in 2019 show that China’s sudden cardiac deaths are as high as 550,000 each year.
According to the 2019 China Cardiovascular Health According to the calculation of "Report of Diseases and Diseases", the number of patients with cardiovascular diseases in China has reached 330 million
.
In recent years, the number of patients with cardiovascular diseases in China has continued to increase.
Therefore, relevant departments in China have begun to pay more and more attention to the prevention, control and treatment of cardiovascular and cerebrovascular diseases, and have issued a series of documents
.
For example, in the "Healthy China Action (2019-2030)", specific instructions are given for the prevention and treatment of cardiovascular and cerebrovascular diseases, and it is clear that the "three highs" co-management should be promoted to carry out overweight and obesity, increased blood pressure and blood sugar, and dyslipidemia.
Disease risk assessment and intervention guidance, and standardized management of hypertension, diabetes, and dyslipidemia
.
It is worth noting that, at the same time, with favorable policies and the continuous expansion of market space, a large number of domestic enterprises have also begun to accelerate their deployment in this field
.
Rurunmed Medical is committed to building a professional vascular interventional surgery robot company, and is currently focusing on the design, development and commercialization of coronary artery functional diagnosis and treatment products
.
It is reported that through long-term adherence to independent research and development, it is committed to building a leader in vascular interventional surgery robots
.
At present, the platform function of its vascular interventional surgical robot and the advanced concept of unmanned operating room have attracted the attention of many domestic and foreign technology companies, and they have proposed to establish a strategic partnership with Runmed Medical
.
Recently, reports have shown that Runmaid Medical has successively cooperated with Ping An Capital, a well-known domestic private equity investment platform, GE Healthcare China, a multinational technology giant, China Resources Medical Devices, a domestic medical device service platform, pharmaceutical circulation company Jointown Medical Devices, and cardiovascular hospitals.
Many companies such as the investment management agency Hanxi Putai have established strategic partnerships
.
Among them, China Resources said that the field of cardiovascular and cerebrovascular devices is one of the key development directions of China Resources Medical Devices, and the cooperation with Runmaid Medical will bring the platform to the world's forefront diagnosis and treatment products.

.
After the signing of strategic cooperation between Runmad Medical and China Resources Medical Devices, in the future, they will deepen their exchanges and continue to introduce new products to make their product coverage more comprehensive and maintain their strong competitiveness in the market
.
The person in charge of Jointown Medical Devices also said that the cooperation with Runmad Medical is very safe and reliable.
It is hoped that in the future cooperation, the two parties can establish a first-line intercommunication channel as soon as possible, do a good job in business docking, use their own resource advantages, and continuously Innovate and dig deep into value to build a national professional cardiovascular medical equipment supply chain
.
It is worth mentioning that in addition to attracting a large number of companies to cooperate, the rapid growth of Runmad Medical in recent years has also attracted extensive attention from investment institutions
.
It is reported that Ping An Capital recently invested tens of millions of U.
S.
dollars to lead the round D financing of Runmed Medical, and well-known foreign asset management institutions followed the investment
.
In addition, at the beginning of this year, the company also received hundreds of millions of yuan in Series C financing led by Jinglin Assets and continued investment by Tongchuangweiye and other old shareholders
.
The industry believes that after multiple rounds of financing, the valuation of Runmad Medical will be greatly increased, and various tasks will be accelerated
.
In general, through a series of strategic cooperation, Runmed Medical is building a high-end "circle of friends" in the field of precision diagnosis and treatment
.
It is expected that in the future, by jointly promoting capital operation, technological innovation, marketing, and channel construction, it will accelerate its ecological construction and strategic landing of vascular interventional surgery robots, which will better empower clinicians and benefit patients with cardiovascular diseases at home and abroad
.